Paul F. Lizzul - Sep 14, 2023 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role: Chief Medical Officer
Signature: /s/ Eric Loumeau, Attorney-in-Fact
Stock symbol: ANAB
Transactions as of: Sep 14, 2023
Transactions value $: -$41,005
Form type: 4
Date filed: 9/18/2023, 06:14 PM
Previous filing: Jan 10, 2023
Next filing: Jan 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANAB	Common Stock	Options Exercise		+6K	+227.96%		8.63K	Sep 14, 2023	Direct	F1, F2
transaction	ANAB	Common Stock	Sale	-$41K	-2.11K	-24.39%	$19.48	6.53K	Sep 14, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANAB	Restricted Stock Unit	Options Exercise	$0	-6K	-50%	$0.00	6K	Sep 14, 2023	Common Stock	6K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2	Reflects the acquisition of 881 shares acquired under the Company's ESPP.
F3	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4	50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.